{"log_id": 1121658854711758390, "direction": 0, "words_result_num": 43, "words_result": [{"probability": {"variance": 3.2e-05, "average": 0.997614, "min": 0.973619}, "location": {"width": 723, "top": 217, "height": 26, "left": 250}, "words": "口服托莫西汀后吸收良好,受食物的影响很小它主要通过氧化代谢清除,包括细胞"}, {"probability": {"variance": 0.000316, "average": 0.993425, "min": 0.889658}, "location": {"width": 762, "top": 255, "height": 25, "left": 209}, "words": "色素P4502D6(CYP2D6酶途径和随后的葡萄糖醛酸化。托莫西汀的半衰期约为5小"}, {"probability": {"variance": 0.000935, "average": 0.990665, "min": 0.808601}, "location": {"width": 763, "top": 293, "height": 27, "left": 209}, "words": "时。小部分为CYP2D6代谢的药物的弱代谢(PM)人群(大约7%的高加索人和2%的非"}, {"probability": {"variance": 0.007583, "average": 0.980596, "min": 0.431863}, "location": {"width": 762, "top": 332, "height": 26, "left": 209}, "words": "洲籍美国人,中国人群CYP2D6代谢为PM的发生率约为1%)与正常代谢人群[强代谢"}, {"probability": {"variance": 0.004262, "average": 0.982789, "min": 0.646031}, "location": {"width": 736, "top": 372, "height": 25, "left": 235}, "words": "EM)]相比,这群人的代谢行为减慢,表现为高10倍的AUC、高5倍的最大血浆浓度"}, {"probability": {"variance": 0.003257, "average": 0.981831, "min": 0.664328}, "location": {"width": 752, "top": 410, "height": 27, "left": 219}, "words": "和较慢的清除率(血浆半衰期大约为24小时)抑制CYP2D6的药物,如氟西汀、帕罗西"}, {"probability": {"variance": 0.00043, "average": 0.987089, "min": 0.931256}, "location": {"width": 254, "top": 449, "height": 24, "left": 208}, "words": "汀和奎尼丁会引起同样的增高"}, {"probability": {"variance": 0.001142, "average": 0.989293, "min": 0.816669}, "location": {"width": 722, "top": 485, "height": 26, "left": 250}, "words": "对参加某些临床试验的400多名儿童和青少年进行了托莫西汀药代动力学的评价,主"}, {"probability": {"variance": 0.000422, "average": 0.993265, "min": 0.869026}, "location": {"width": 762, "top": 523, "height": 27, "left": 209}, "words": "要选用了人群药代动力学研究。也获得了儿童、青少年和成人的单剂量和稳态的个体药代"}, {"probability": {"variance": 0.010324, "average": 0.96928, "min": 0.446944}, "location": {"width": 761, "top": 561, "height": 27, "left": 211}, "words": "动力学数据。在以mg/kg标准计的剂量下,在儿童、青少年和成人中观察到相似的半衰"}, {"probability": {"variance": 0, "average": 0.992585, "min": 0.992585}, "location": {"width": 23, "top": 602, "height": 23, "left": 211}, "words": "期"}, {"probability": {"variance": 0.005795, "average": 0.97916, "min": 0.626363}, "location": {"width": 427, "top": 600, "height": 24, "left": 301}, "words": "和AUC。经体重校正后的清除率和分布容积也相似"}, {"probability": {"variance": 0.006667, "average": 0.98068, "min": 0.505818}, "location": {"width": 724, "top": 635, "height": 30, "left": 248}, "words": "吸收和分布一口服托莫西汀后迅速吸收。在EM和PM的绝对生物利用度分别约为"}, {"probability": {"variance": 0.016423, "average": 0.953546, "min": 0.441546}, "location": {"width": 471, "top": 676, "height": 25, "left": 214}, "words": "63%和9496。服用后,大约在1-2小时达到最大血浆浓度"}, {"probability": {"variance": 0.000282, "average": 0.994319, "min": 0.925124}, "location": {"width": 723, "top": 711, "height": 31, "left": 249}, "words": "盐酸托莫西汀可与食物同时或分开服用。对于成人,盐酸托莫西汀与标准的高脂肪饮"}, {"probability": {"variance": 0.003056, "average": 0.976595, "min": 0.765525}, "location": {"width": 757, "top": 749, "height": 32, "left": 214}, "words": "食一起服用不影响托莫西汀的口服吸收程度(AUC),但确实减少吸收速率,使Cmax下降"}, {"probability": {"variance": 0.010031, "average": 0.975893, "min": 0.391799}, "location": {"width": 754, "top": 786, "height": 33, "left": 216}, "words": "7%,Tmax延迟3小时在临床研究中,儿童和青少年同时服用盐酸托莫西汀和食物,会"}, {"probability": {"variance": 0.008421, "average": 0.945664, "min": 0.72217}, "location": {"width": 134, "top": 829, "height": 26, "left": 213}, "words": "使Cmax降低99"}, {"probability": {"variance": 0.000139, "average": 0.993384, "min": 0.949881}, "location": {"width": 701, "top": 861, "height": 35, "left": 250}, "words": "静脉注射给药后,稳态分布容积为0.85Lkg,提示托莫西汀主要分布在全身体液中"}, {"probability": {"variance": 0.00165, "average": 0.977374, "min": 0.875565}, "location": {"width": 425, "top": 903, "height": 30, "left": 212}, "words": "校正体重后,同一体重范围内的患者分布容积相似"}, {"probability": {"variance": 0.002244, "average": 0.980793, "min": 0.779137}, "location": {"width": 572, "top": 938, "height": 33, "left": 252}, "words": "在治疗浓度血浆中,98%的托莫西汀与蛋白结台,主要与白蛋白结合"}, {"probability": {"variance": 0.005686, "average": 0.969791, "min": 0.648536}, "location": {"width": 706, "top": 974, "height": 36, "left": 250}, "words": "代谢和清除一托莫西汀主要通过CYP2D6酶途径代谢。与正常代谢行为人群(EM"}, {"probability": {"variance": 0.0044, "average": 0.982808, "min": 0.579281}, "location": {"width": 760, "top": 1014, "height": 34, "left": 214}, "words": "相比,在此途径的慢代谢人群(PM)中,会有较高的托莫西汀血浆浓度,与EM人群相"}, {"probability": {"variance": 0.004137, "average": 0.965353, "min": 0.762975}, "location": {"width": 442, "top": 1057, "height": 26, "left": 213}, "words": "比,在PM人群,托莫西汀的AUC大约高10倍,C"}, {"probability": {"variance": 0.015386, "average": 0.945534, "min": 0.58626}, "location": {"width": 232, "top": 1053, "height": 24, "left": 740}, "words": "约高5倍,实验室检查可以"}, {"probability": {"variance": 0.003971, "average": 0.985106, "min": 0.587186}, "location": {"width": 761, "top": 1088, "height": 36, "left": 212}, "words": "鉴别CYP2D6PM盐酸托莫西汀与港在的CYP2D6抑制剂联合使用,如氟西汀、帕罗西"}, {"probability": {"variance": 0.001131, "average": 0.983566, "min": 0.856593}, "location": {"width": 660, "top": 1126, "height": 34, "left": 215}, "words": "汀或奎尼丁会引起托莫西汀血浆浓度的实质性升高,有必要调节给药剂量(见"}, {"probability": {"variance": 0.004165, "average": 0.974414, "min": 0.737617}, "location": {"width": 408, "top": 1166, "height": 32, "left": 213}, "words": "作用】)。托莫西汀对CYP2D6途径不抑制或削弱"}, {"probability": {"variance": 0.005611, "average": 0.975161, "min": 0.676404}, "location": {"width": 568, "top": 1202, "height": 32, "left": 255}, "words": "无论CYP2D6状态如何,形成的主要氧化代谢产物都是4羟托莫西"}, {"probability": {"variance": 0.028694, "average": 0.792309, "min": 0.580076}, "location": {"width": 153, "top": 1190, "height": 35, "left": 858}, "words": "该产物被号"}, {"probability": {"variance": 0.011947, "average": 0.945464, "min": 0.565078}, "location": {"width": 742, "top": 1236, "height": 38, "left": 214}, "words": "萄糖醛酸化。作为去甲肾上腺素转运体抑制剂,4轻托莫西汀与托莫西汀具有向等效能"}, {"probability": {"variance": 0, "average": 0.891512, "min": 0.891512}, "location": {"width": 73, "top": 1224, "height": 33, "left": 952}, "words": "公"}, {"probability": {"variance": 0.014291, "average": 0.95069, "min": 0.461103}, "location": {"width": 800, "top": 1276, "height": 33, "left": 211}, "words": "但在血浆中浓度很低(在EM中为托莫西汀浓度的1%,在PM中为托莫源江浓度的5"}, {"probability": {"variance": 0.002422, "average": 0.984479, "min": 0.698265}, "location": {"width": 683, "top": 1313, "height": 33, "left": 293}, "words": "-羟托莫西汀主要由CYP2D6催化形成,但在PM中,有较低比率的4羟托莫西汀"}, {"probability": {"variance": 0.007304, "average": 0.965421, "min": 0.555423}, "location": {"width": 757, "top": 1351, "height": 33, "left": 215}, "words": "由其他细胞色素P450酶代谢而成,N-去甲基托莫西汀由CYP2C19和其他细胞色素P450"}, {"probability": {"variance": 0.003816, "average": 0.975704, "min": 0.673956}, "location": {"width": 909, "top": 1380, "height": 67, "left": 213}, "words": "酶代谢而成,但是,与托莫西汀相比药理活性非常低在血浆中的浓度也较低(在中广州医药"}, {"probability": {"variance": 0.012436, "average": 0.955791, "min": 0.465394}, "location": {"width": 463, "top": 1427, "height": 32, "left": 217}, "words": "为托莫西汀浓度的5%、在PM中为托莫西汀浓度的450"}, {"probability": {"variance": 1e-06, "average": 0.999429, "min": 0.997975}, "location": {"width": 145, "top": 1420, "height": 59, "left": 969}, "words": "有限公司"}, {"probability": {"variance": 0.014714, "average": 0.948039, "min": 0.363311}, "location": {"width": 724, "top": 1462, "height": 33, "left": 256}, "words": "成人口服后,在EM人群中,托莫西汀的平均表观血浆清除率为0.35L/hrkg平均半"}, {"probability": {"variance": 0.014527, "average": 0.668036, "min": 0.510958}, "location": {"width": 221, "top": 1513, "height": 65, "left": 555}, "words": "/混贸城"}, {"probability": {"variance": 0, "average": 0.959071, "min": 0.959071}, "location": {"width": 138, "top": 1527, "height": 95, "left": 615}, "words": "限"}, {"probability": {"variance": 0, "average": 0.966173, "min": 0.966173}, "location": {"width": 28, "top": 1531, "height": 31, "left": 961}, "words": "程"}, {"probability": {"variance": 0.015246, "average": 0.915539, "min": 0.702832}, "location": {"width": 263, "top": 1558, "height": 80, "left": 902}, "words": "仅供存档"}], "language": 3}